drugset / Trial / NCT03690739
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
RandomizedParallel-groupOpen-labelPrevention
Summary
This is an open-label, prospective, randomized, controlled, parallel group, multi-center phase III trial to evaluate the Symptom Benefit Rate of trabectedin/PLD in patients with recurrent ovarian cancer who achieve a stabilization of disease after 3 cycles of platinum-based reinduction therapy and with no clinical benefit.
Timeline
- Start
- 2019-08-09
- Primary completion
- 2021-03-03
- Completion
- 2021-03-03
Outcome
Outcome not reported
Stopped (Enrollment): “Insufficient Recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pegylated liposomal doxorubicin | Unknown | 30 mg/m2 | — |
| Comparator | Trabectedin | Small molecule | 1.1 mg/m2 | — |
| Comparator | Bevacizumab | Monoclonal antibody | — | — |
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Cisplatin | Other / unclassified | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |